Revvity, Inc. announced a new license agreement with AstraZeneca for the technology underlying its Pin-point base editing system, a next-generation modular gene editing platform with a strong safety profile.
Dr. Alan Fletcher, Senior Vice President, Life Sciences at Revvity, said, “Our fundamental goal for the Pin-point platform is to translate the technology from pre-clinical research into the clinic, and ultimately, impact patient lives. In that vein, we are delighted to announce this non-exclusive agreement with AstraZeneca to support their creation of cell therapies for the treatment of cancer and immune-mediated diseases.”